Generated by AI
Alvotech SA is a biotechnology company focused on the development and manufacture of biosimilar medicines. Alvotech SA specializes in creating high-quality, cost-competitive alternatives to established biologic therapies, with products and candidates spanning autoimmune diseases, eye disorders, osteoporosis, respiratory disease, oncology, and other therapeutic areas. The company operates a vertically integrated model that covers the biosimilar value chain from cell line development and research to commercial manufacturing. Its portfolio includes monoclonal antibodies and fusion proteins designed to support treatment access across global patient markets. Alvotech SA works through strategic partnerships to extend commercialization and distribution reach across North America, Europe, Asia, and other international markets. Headquartered in Luxembourg, Alvotech SA plays a role in expanding access to biosimilar medicines within the global biopharmaceutical sector.
Website9, Rue de Bitbourg
Luxembourg, 1273
Luxembourg
The latest articles about ALVO.
Summary of Oct 20's posts. Generated by AI.
No summary yet.
No summary yet.
Summary of Nov 3's posts. Generated by AI.
Investors talking about ALVO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.